Market Newsdesk

A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses

Change in BMI and
Body Weight
Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use

No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks

Additional Cohorts Being Added to Determine Maximum Tolerated Dose

CAMBRIDGE, Mass.
, April 22, 2025 /PRNewswire/ — MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today reported additional top-line results from the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), further demonstrating its potential as a best-in-class obesity drug.

In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive trend in body weight (BW) reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index (BMI), which shows body weight adjusted for height, showed a difference between the treatment group and the placebo (PBO) group, which was even more pronounced, further supporting the dose-dependent effect of the drug on weight-related outcomes. Of note, DA-1726 did not show any clinically significant increases in heart rate (HR) or QTcF changes up to 32 mg at 4 weeks of administration.

As previously reported, with no titration, DA-1726, with its novel 3:1 ratio between GLP-1R and GCGR at the 32 mg dose, demonstrated compelling maximum weight loss of -6.3% and mean weight loss of -4.3% at Day 26 (p=0.0005), while showing a strong signal of GLP-1R efficacy with maximum lowering of fasted glucose of -18 mg/dL and mean lowering of -5.3 mg/dL at Day 26, and maximum waist circumference reduction of 3.9 inches and mean reduction of 1.6 inches, indicating a strong signal of glucagon efficacy at Day 33.

“This new, additional Phase 1 MAD data further highlights DA-1726’s potential to be a best-in-class obesity treatment, showing impressive weight loss results, particularly in terms of BMI reduction,” stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. “Specifically, there was a clear dose-dependent effect on body weight loss between 8 mg and 32 mg, with higher doses leading to greater weight reduction. BMI change from baseline showed the difference between the drug group and the placebo group was even more noticeable. Based on the robust safety and tolerability profile of DA-1726, we believe that 32 mg will likely be the starting dose for future clinical trials.”

Mr. Kim continued, “Additionally, activation of either the GLP-1 or glucagon receptors is known to increase heart rate. As a result, dual agonists that simultaneously activate both receptors may raise concerns about excessive heart rate elevation and potential QT interval prolongation. For example, at least one similar dual agonist in clinical trials was discontinued due to an increase in heart rate and other safety concerns. In contrast, the mean heart rate of subjects on DA-1726 showed a slight decrease from baseline in all treatment groups other than the 16 mg cohort where the baseline was significantly lower than other cohorts; the mean decrease after 4 weeks was -14 to -0.7 beats per min (bpm) in the DA-1726 cohorts (4, 8 or 32 mg once weekly) while there was an increase of 7.7 bpm for DA-1726 16 mg cohort. There were no onsets reported in the QTcF (QT interval corrected for heart rate using the method of Fridericia) interval categories >480–500 msec or >500 msec and no risk of cardiovascular events was identified.”

Management also noted that DA-1726’s 3:1 balanced activation of GLP-1 and glucagon receptors offers a promising alternative to current GLP-1 agonists, addressing the significant tolerability challenges that lead to 20–30% discontinuation within the first month and up to 70% within a year. As previously reported, a Phase 1 Part 3 study is planned to evaluate DA-1726 patients who discontinued Wegovy® early, aiming to demonstrate improved tolerability, safety, and weight loss outcomes. Additionally, higher-dose cohorts will be included to assess the maximum tolerated dose and fully realize DA-1726’s potential as higher doses may also show a similar profile, while potentially demonstrating increased weight reduction.

The Phase 1 trial was a randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. The MAD portion of the study enrolled healthy adults with a minimum body mass index between BMI 30 – 45 kg/m². The primary endpoint of the Phase 1 trial was to assess the safety and tolerability of DA-1726 by monitoring adverse events (AEs), serious adverse events (SAEs), treatment emergent adverse events (TEAEs) and AEs leading to treatment discontinuation. Secondary endpoints included the PK of DA-1726, assessed via serum concentrations over time and metabolite profiling at the highest doses of DA-1726. Exploratory endpoints included the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI), among others.

As previously disclosed, in the 28-day, 36-subject MAD portion of the study, DA-1726 demonstrated excellent safety and tolerability, with positive clinical activity. Four out of six subjects on the 32 mg dose experienced mild gastrointestinal (GI) AEs after the first 32 mg dose, most of which were resolved after 24 hours of occurrence. There were no treatment-related discontinuations or SAEs. Early satiety was observed in 83% of subjects receiving the 32 mg dose, suggesting the potential for greater weight loss with longer treatment duration.

Mr. Kim concluded, “After our initial top-line data was announced pre-market on April 15, 2025, the Company’s previously issued and outstanding pre-funded warrants were exercised for 1,430,000 shares of the Company’s common stock — leaving no pre-funded warrants outstanding. We continue to believe that the body of data for DA-1726 provides a compelling case for its future potential as a treatment for obesity.”

For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06252220.

About DA-1726
DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®) and cotadutide (another OXM analogue). Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “potential”, “intends”, “projects”, “plans”, “estimates” or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia’s ability to execute on its commercial strategy; our expectations regarding the sufficiency of our existing cash on hand to fund our operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia’s current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia’s contract manufacturers, clinical study partners and others involved in the development of MetaVia’s current and future product candidates; potential negative interactions between MetaVia’s product candidates and any other products with which they are combined for treatment; MetaVia’s ability to initiate and complete clinical trials on a timely basis; MetaVia’s ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia’s clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia’s stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia’s filings with the Securities and Exchange Commission, including MetaVia’s most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia

Marshall H. Woodworth

Chief Financial Officer
+1-857-299-1033
[email protected]

Rx Communications Group


Michael Miller

+1-917-633-6086
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-reports-additional-positive-top-line-results-from-the-mad-part-2-of-its-phase-1-study-of-da-1726-a-novel-31-ratio-glp-1-and-glucagon-dual-receptor-agonist-to-treat-obesity-further-demonstrating-its-best-in-class-potenti-302433906.html

SOURCE MetaVia Inc.

TORONTO
, April 22, 2025 /CNW/ – BMO Asset Management Inc., as manager of the BMO ETFs, and BMO Investments Inc., as manager of the BMO Mutual Funds, today announced the April 2025 cash distribution for unitholders of BMO ETFs and unitholders of exchange-traded series of units of the BMO Mutual Funds (collectively, the “ETF Series”) that distribute monthly, as set out in the table below. Unitholders of record of the BMO ETFs and the ETF Series of the BMO Mutual Funds at the close of business on April 29, 2025 will receive cash distributions payable on May 2, 2025.

The ex-dividend date and record date for all BMO ETFs and ETF Series of BMO Mutual Funds is April 29, 2025.

Details of the per unit cash distribution amount are as follows:

Monthly Distributions

*Cash distribution per unit ($) amounts are USD for ZJK.U, ZPR.U, ZIC.U, ZUAG.U, ZUP.U, ZWB.U, ZMI.U, ZPAY.U, ZUS.U, ZUCM.U, ZDY.U, ZWH.U, and ZPW.U.

Further information about BMO ETFs and ETF Series of the BMO Mutual Funds can be found at www.bmoetfs.com.

Commissions, management fees and expenses all may be associated with investments in BMO ETFs and ETF Series of the BMO Mutual Funds.  Please read the applicable ETF Facts document or prospectus before investing.  BMO ETFs and ETF Series of the BMO Mutual Funds are not guaranteed, their values change frequently, and past performance may not be repeated. For a summary of the risks of an investment in the BMO ETFs or ETF Series of the BMO Mutual Funds, please see the specific risks set out in the simplified prospectus.  Units of the BMO ETFs and ETF Series securities of the BMO Mutual Funds may be bought and sold at market price on a stock exchange and brokerage commissions will reduce returns. Distributions are not guaranteed and are subject to change and/or elimination.  

BMO ETFs are managed by BMO Asset Management Inc., which is an investment fund manager and a portfolio manager, and a separate legal entity from Bank of Montreal. The ETF Series of the BMO Mutual Funds are managed by BMO Investments Inc., which is an investment fund manager and a separate legal entity from Bank of Montreal.

“BMO (M-bar roundel symbol)” is a registered trademark of Bank of Montreal, used under licence.

About BMO Financial Group

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of January 31, 2025. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.

SOURCE BMO Financial Group

• 
  Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session
  
• 
  Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation over breast conserving surgery
  
• 
  In-booth expert exchange session on breast cancer cryoablation from the perspective of both breast surgeons and interventional oncologists by Sophie Wooldrik, MD & Prof. Tomas Vogl, MD respectively
  
• 
  Three hands-on device trainings, including ProSense®
  

CAESAREA, Israel
, April 22, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the European Conference on Interventional Oncology 2025 (ECIO), which took place on April 13 – 16, 2025 in Rotterdam, the Netherlands. One of the major areas of focus at ECIO 2025 was breast cancer cryoablation, with ProSense® featuring in seven key events at the conference.

“As minimally invasive technologies like ProSense® have advanced the science of cancer care, interventional oncology is becoming an increasingly viable and preferred pathway for the treatment of breast cancer in Europe, next to current standard of care surgical, medical, and radiological methods,” stated Eyal Shamir, IceCure’s Chief Executive Officer. “We believe ProSense® is the leading cryoablation system for early-stage breast cancer tumors on the market today, and this was reflected in the number of sessions in which our cryoablation system was featured. We believe that this points to the continued commercial adoption of ProSense® for indications including breast cancer in Europe and other key global markets.”

ProSense® was featured in the following.

Two scientific sessions and one poster presentation presenting data from investigator-initiated studies that used ProSense® for breast cancer:

• Oral presentation and Q&A by Dr. Sophie M. Wooldrik of the Netherlands, titled: Review of the indications and results of the different techniques of thermal ablation on breast tumors; The treatment of breast cancer with percutaneous thermal ablation – THERMAC; An open label phase 2 screening trial
  • Conclusion: Only cryoablation met the requirement to proceed to a phase 3 study, with an efficacy rate of 94%, a complication rate of 0%, and a 100% treatment tolerance. 94% of patients were very satisfied or satisfied with the thermal ablation technique, and 95% of patients stated they would choose thermal ablation over breast conserving surgery. 41 women were enrolled in the study, which compared cryoablation to radiofrequency ablation and microwave ablation.
• Oral presentation and Q&A by Professor Thomas J. Vogl of Germany, titled: CT-guided cryoablation of primary breast cancer: Evaluation of efficacy and safety 
  • Conclusion: Cryoablation is a safe and effective treatment for primary breast cancer. 45 patients with 56 tumors (mean diameter 1.6 ± 0.7 cm) were treated. The mean overall progression-free survival was 2.9 years (95% with a confidence interval of 2.3-3.6).

Poster presentation titled: Non-surgical treatment of breast cancer: a comparison of outcomes between cryoablation with hormonal therapy versus cryoablation alone and hormonal therapy alone in patients not eligible for surgery

• Conclusion: Cryoablation with hormonal therapy reduces tumor size and residual disease more effectively than hormonal therapy or cryoablation alone, making it a promising option for patients not eligible for surgery. 64 patients were not suitable for surgery, and a total of 73 tumors (mean 14.8 mm) were treated. Tumor size reduction was greatest in the cryoablation with hormone therapy (HT) group (94%, mean-reduction of 15.4 mm), followed by cryoablation only (82%, mean reduction of 9.7 mm), and followed by HT only (43%, mean reduction of 4.6 mm).

ProSense® featured during ECIO’s Hands-On Device Cryoablation Training Sessions.

The sessions were well attended, and the training was well received.

An in-booth expert exchange session at IceCure’s booth was conducted on the perspectives of breast cancer cryoablation from breast surgeons and interventional oncologists by Dr. Wooldrik and Professor Vogl, who had also presented at the scientific sessions.

About ProSense®

The ProSense® Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors.

About IceCure Medical

IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and China.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that minimally invasive technologies such as ProSense have advanced cancer care; the belief that ProSense is the leading cryoablation system for early-stage breast cancer tumors on the market today; and the belief that there will likely be continued commercial adoption of ProSense® for indications, including breast cancer, in Europe and other key global markets. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company’s planned level of revenues and capital expenditures; the Company’s available cash and its ability to obtain additional funding; the Company’s ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company’s ability to maintain its relationships with suppliers, distributors and other partners; the Company’s ability to maintain or protect the validity of its patents and other intellectual property; the Company’s ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:
Email: [email protected]

Michael Polyviou
Phone: 732-232-6914

Todd Kehrli
Phone: 310-625-4462

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/icecures-prosense-featured-at-european-conference-on-interventional-oncology-with-an-emphasis-on-breast-cancer-cryoablation-302434222.html

SOURCE IceCure Medical

TOKYO
, April 22, 2025 /PRNewswire/ — TOYO Co., Ltd (Nasdaq: TOYO) (OTC: TOYWF) (“TOYO” or the “Company”), a solar solution company, has officially started production at its new facility in Ethiopia in early April 2025. The company is scheduled to deliver more than 80 MW of solar cells to customers by the end of April.

Following the initial deliveries, TOYO plans to ramp up operations significantly. By May and June 2025, the new Ethiopian plant is expected to be fully operational, with a monthly production capacity of 150 to 200 MW. The company recently announced that it is expanding its nameplate capacity at this location to 4GW based on robust external customer demand and the internal needs of its new module facility in Houston Texas. This expansion aligns with TOYO’s broader strategy to strengthen its global solar manufacturing footprint and meet increasing demand for renewable energy solutions.

TOYO’s entry into Ethiopia marks a strategic move to diversify manufacturing locations and leverage regional advantages, supporting sustainable energy growth globally.

“We are very positive about the strong demand we are seeing in the market and are working diligently to execute the additional 2GW expansion in Ethiopia,” said Junsei Ryu, Chairman and CEO of TOYO Co., Ltd. “2025 is shaping up to be a year of massive growth for TOYO fueled by solar power’s ability to rapidly add low-cost power to the grid and our commitment to sustainable energy solutions on a global scale.”

About TOYO Co., Ltd.

TOYO is a solar solutions company that is committed to becoming a full-service solar solutions provider in the global market, integrating the upstream production of wafers and silicon, midstream production of solar cells, downstream production of photovoltaic modules, and potentially other stages of the solar power supply chain. TOYO is well-positioned to produce high-quality solar cells at a competitive scale and cost.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include but are not limited to, statements regarding the expected growth of TOYO, the expected order delivery of TOYO products, TOYO’s construction plan for new facilities and anticipated commencement of production. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of TOYO’s management and are not predictions of actual performance.

These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although TOYO believes that it has a reasonable basis for each forward-looking statement contained in this press release, TOYO caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the documents filed by TOYO from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

TOYO cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to several risks and uncertainties, including, among others, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of TOYO, and other risks and uncertainties, including but not limited to those included under the heading “Risk Factors” of the filings of TOYO with the SEC. There may be additional risks that TOYO does not presently know or that TOYO currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of TOYO as of the date of this press release. Subsequent events and developments may cause those views to change. However, while TOYO may update these forward-looking statements in the future, there is no current intention to do so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of TOYO as of any date subsequent to the date of this press release. Except as may be required by law, TOYO does not undertake any duty to update these forward-looking statements.

Contact Information:

For TOYO Co., Ltd.


[email protected]
 

Crocker Coulson
Email: [email protected]
Tel: (646) 652-7185

View original content:https://www.prnewswire.com/news-releases/toyo-commences-production-in-its-2gw-solar-cell-facility-in-ethiopia-302434451.html

SOURCE TOYO Co., Ltd

Company’s partnership with Trex

^®
 and Home Repair Services highlights how plastic grocery bags can be converted into accessibility ramps for Veterans’ homes

GRAND RAPIDS, Mich., April 22, 2025 /PRNewswire/ — Food solutions company SpartanNash^® (the “Company”) (Nasdaq: SPTN) once again joined forces with Home Repair Services and Trex^® Company in honor of Earth Day, transforming plastic grocery bags recycled at Company-operated stores into accessibility ramps for Veterans in need. 

“By upcycling returned plastic bags into accessibility ramps for Veterans, we are giving the gift of mobility in a sustainable, eco-friendly way,” said SpartanNash Chief Communications Officer Adrienne Chance. “It’s a People First program that brings our store guests, Associates, nonprofit partners and community together to serve.”

The ramp – which was constructed by SpartanNash Associate volunteers – will provide a safer home to a West Michigan Veteran, who served in the U.S. Marines during the Vietnam War era.

Each ramp requires approximately 157,500 recycled bags, which are collected year-round at SpartanNash-operated stores including Family Fare^®, Martin’s Super Market, D&W^® Fresh Market and Forest Hills Foods^®. Trex, an eco-friendly decking company, then turns these plastic bags – which include produce bags, cereal box liners, bubble wrap and more – into composite decking boards. SpartanNash Associates then partner with Home Repair Services, a West-Michigan based organization providing income-based home repairs for those in need, to build the accessibility ramps.

“Sustainability is at the core of everything we do – and this project exemplifies how recycling can create real, tangible impact,” said Dave Heglas, Senior Director of Recycled Materials at Trex Company. “By transforming everyday plastic waste into something as meaningful as accessible home ramps for Veterans, we’re not just reducing landfill waste – we’re building pathways to better lives. We’re honored to be part of a collaboration that brings together environmental responsibility and community care in such a powerful way.”

In 2024, SpartanNash built accessibility ramps for five Veterans in West Michigan. This year, the food solutions company will expand the ‘Bags to Boards’ program to other communities in its footprint, building ramps in West Michigan and beyond.

More than 5,000 pounds of plastic bags have been recycled at the Company’s stores since 2023. More information regarding SpartanNash’s recycling initiatives can be found in SpartanNash’s Corporate Responsibility Report.

About SpartanNash
SpartanNash (Nasdaq: SPTN) is a food solutions company that delivers the ingredients for a better life. Committed to fostering a People First culture, the SpartanNash family of Associates is 20,000 strong. SpartanNash operates two complementary business segments – food wholesale and grocery retail. Its global supply chain network serves wholesale customers that include independent and chain grocers, national retail brands, e-commerce platforms, and U.S. military commissaries and exchanges. The Company distributes products for every aisle in the grocery store, from fresh produce to household goods to its OwnBrands, which include the Our Family^® portfolio of products. On the retail side, SpartanNash operates nearly 200 brick-and-mortar grocery stores, primarily under the banners of Family Fare, Martin’s Super Markets and D&W Fresh Market, in addition to dozens of pharmacies and fuel centers with convenience stores. Leveraging insights and solutions across its segments, SpartanNash offers a full suite of support services for independent grocers. For more information, visit spartannash.com.

Trex^® is a registered trademark of Trex Company, Inc.

CONTACT:

Adrienne Chance 
SVP and Chief Communications Officer
SpartanNash
[email protected]  

View original content to download multimedia:https://www.prnewswire.com/news-releases/bags-to-boards-spartannash-celebrates-earth-day-with-second-annual-accessibility-ramp-build-302433745.html

SOURCE SpartanNash